Cracks down on false drug ads by social media influencers and healthcare providers.
This bill would fine social media influencers and healthcare providers if they share wrong or confusing information about prescription drugs. It would also make drug companies and providers publicly share payments for promoting drugs. The goal is to give the Food and Drug Administration (FDA) more power to check drug ads on social media.
Today, social media influencers and healthcare providers might not face specific civil penalties for false or misleading drug ads. Also, payments they receive for promotions aren't always publicly reported. Telehealth companies might also not be explicitly covered by certain drug advertising rules. After this bill, influencers and providers would face civil penalties for false or misleading drug communications, and payments for drug promotion would be publicly reported. The Food and Drug Administration would also get $15,000,000 annually for five years to increase its oversight of digital drug advertising.
S 652 · 119th Congress · February 20, 2025 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
11 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.